title: Global Immunization Vision and Strategy (GIVS): a mid-term analysis of progress in 50 countries.
abstract: Within the overall framework set out in the Global Immunization Vision and Strategy (GIVS) for the period 2006-2015, over 70 countries had developed comprehensive Multi-Year Plans (cMYPs) by 2008, outlining their plans for implementing the GIVS strategies and for attaining the GIVS Goals at the midpoint in 2010 or earlier. These goals are to: (1) reach ≥90% and ≥80% vaccination coverage at national and district level, respectively; and (2) reduce measles-related mortality by 90% compared with the 2000 level. Fifty cMYPs were analysed along the four strategic areas of the GIVS: (1) protecting more people in a changing world; (2) introducing new vaccines and technologies; (3) integrating immunization, other health interventions and surveillance in the health system context; and (4) immunizing in the context of global interdependence. By 2010, all 50 countries planned to have introduced hepatitis B (HepB) vaccine, 48 the Haemophilus influenzae type B (Hib) vaccine and only a few countries had firm plans to introduce pneumococcal or rotavirus vaccines. Countries seem to be inadequately prepared in terms of cold-chain requirements to deal with the expected increases in storage that will be required for vaccines, and in making provisions to establish a corresponding surveillance system for planned new vaccine introductions. Immunization contacts are used to deliver other health interventions, especially in the countries in the World Health Organization (WHO) Africa Region. The cost for the planned immunization activities will double to U$27 per infant, of which U$5 per infant is the expected shortfall. Global Alliance for Vaccines and Immunization (GAVI) funding is becoming the largest contributor to immunization programmes.
authors.affiliation: Immunization Vaccines and Biologicals Department (IVB), Expanded Program on Immunization (EPI), World Health Organization, Geneva, Switzerland. kamaral@who.int
authors.forename: Lidija
authors.initials: L
authors.lastname: Kamara
authors.forename: Patrick
authors.initials: P
authors.lastname: Lydon
authors.forename: Julian
authors.initials: J
authors.lastname: Bilous
authors.forename: Jos
authors.initials: J
authors.lastname: Vandelaer
authors.forename: Rudi
authors.initials: R
authors.lastname: Eggers
authors.forename: Marta
authors.initials: M
authors.lastname: Gacic-Dobo
authors.forename: William
authors.initials: W
authors.lastname: Meaney
authors.forename: Jean-Marie
authors.initials: JM
authors.lastname: Okwo-Bele
mesh_terms: D014943:Global Health / Q000706:statistics & numerical data; D018073:Haemophilus Vaccines / Q000627:therapeutic use; D006285:Health Planning / Q000458:organization & administration; D006801:Humans; D007391:International Cooperation; D032541:Mass Vaccination / Q000458:organization & administration* / Q000706:statistics & numerical data; D008457:Measles / Q000401:mortality / Q000517:prevention & control; D008458:Measles Vaccine / Q000627:therapeutic use; D009937:Organizational Objectives; D011159:Population Surveillance; D014761:Viral Hepatitis Vaccines / Q000627:therapeutic use
chemical_list: D018073:Haemophilus Vaccines; D008458:Measles Vaccine; D014761:Viral Hepatitis Vaccines